Clinical Trials at Duke Comprehensive Cancer Center

If you need additional information about any of the trials listed or would like to inquire about other open trials, please contact Karla Morris at (919) 668-8108.

GENITOURINARY

Newly Diagnosed & Early Stage:
Contact: Patricia Creel, RN (919) 668-0635

Advanced/Metastatic:
Contact: Karla Morris, RN (919) 668-8108 (option 1)

HIFU/Surgery:
Contact: Jill Smith (919) 668-3613

Trial Phase Genitourinary Cancers - Prostate cancer and cancers of the kidney, bladder, and male organs
00014357 II A Phase II Randomized Study For Patients With Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery And Concomitant Chemoradiation By Either BID Irradiation Plus 5-Fluorouracil And Cisplatin Or QD Irradiation Plus Gemcitabine Followed By Select
00016752 III A Phase III, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Asymptomatic Patients with Metastatic Castration-Resistant Prostate Cancer (Cougar 302)
00017905 N/A Radiation Therapy Oncology Group RTOG 0841 Efficiency Of Screening For Depression In Cancer Patients Receiving Radiotherapy
00007777 I/II Phase I/II Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer (CA180086)
00007872 III A Comparative Study of PET/CT versus Diagnostic CT for the Detection of Clear Cell Renal Cell Carcinoma in Pre-surgical Patients with Renal Masses Using Iodine-124 labeled Chimeric G250 (124I-cG250)
00007984 II CP18-0601: A Phase 2, Multicenter, Randomized Study of IMC A12 or IMC 1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy
00007163 III A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy XRP6976J/3503 / III
00007416 III Phase 3b, Randomized, Open-Label Study of Bevacizumab (Avastin®) + Temsirolimus (Torisel®) vs. Bevacizumab (Avastin®) + Interferon-Alfa (Roferon®) as First-Line Treatment in Subjects With Advanced Renal Cell Carcinoma
00011630 III A Multicenter, Randomized, Double-Blind, Phase III Study of Sunitinib Plus Prednisone versus Prednisone in Patients with Progressive Metastatic Hormone-Refractory Prostate Cancer After Failure of a Docetaxel-Based Chemotherapy Regimen
00010747 II Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study
00001593 Pilot/Feasibility Impact of Noise Canceling Headphones on Pain Perception and Anxiety Associated with Prostate Needle Biopsy
00003552 I A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen: Determination of I-123 Radiation Dosimetry for I-123-MIP-1072 and I-123-MIP-1095
00003687 II Phase II Randomized Double Blind Placebo-controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer - 07TASQ08
00000310 II An Open Label, Single Arm Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (APC8015F) for Men with Objective Disease Progression on Protocol D9902 Part B
00012130 I A Phase I Dose Escalation Study of Cryotherapy Followed by Radiation Therapy in Patients with Intermediate Risk, Clinically Localized Carcinoma of the Prostate
00006510 I Phase I Dose-Escalation Study of Preoperative RT Followed by Radical Prostatectomy in Patients with High-Risk, Localized Carcinoma of the Prostate.
00000181 II A Phase II Study of Neoadjuvant Bevacizumab plus Docetaxel in High Risk Patients with Prostate Cancer undergoing Radical Prostatectomy
00000100 III XRP6976J/3501 A Multicenter, Open-Label, Randomized, Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (ELIGARD -leuprolide acetate) in Combination with Taxotere (docetaxel) Administered Every Three Weeks Versus Hormonal Therapy Alone Versus D
00008931 II RTOG 0415: A Phase II Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer
00009495 II A Single Arm, Phase II Study of RAD001 in Patients with Metastatic, Hormone-Refractory Prostate Cancer
00000309 III A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (Provenge, APC8015) in Men with Metastatic Androgen Independent Prostatic Adenocarcinoma
00011890 N/A Prospective Validation of a Microarray-Based Docetaxel Response Signature in Metastatic, Hormone-Refractory Prostate Cancer
00008991 I/II A Phase I/II Safety and Pharmacokinetic Study of SU011248 in Combination with Docetaxel (Taxotere) and Prednisone in Patients with Metastatic Hormone Refractory Prostate Cancer (HRPC)
00009388 III CALGB 90202: Randomized Double-Blind, Placebo-Controlled Phase III Study of Early vs Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone.
00000548 I A Single Arm, Phase IB Study of RAD001 and Sunitinib in Patients with Advanced Renal Cell Carcinoma
00000847 III A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients with Metastatic Carcinoma of the Kidney which has Progressed on VE
00001275 II Phase II Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium in Patients with Non-Invasive Urothelial Carcinoma In Situ (CIS) Previously Treated with Bacille Calmette-Guérin (BCG) VB4-845-02-IIA
Duke Comprehensive Cancer Center Accolades